ICD-10 Coding for Acute Myeloblastic Leukemia(C92.00, C92.01, C92.02)
Complete ICD-10-CM coding and documentation guide for Acute Myeloblastic Leukemia. Includes clinical validation requirements, documentation requirements, and coding pitfalls.
Also known as:
Related ICD-10 Code Ranges
Complete code families applicable to Acute Myeloblastic Leukemia
C92.0-C92.9Primary Range
Acute myeloid leukemia codes
This range includes all codes related to acute myeloid leukemia, including specific subtypes and remission statuses.
Other specified and unspecified acute myeloid leukemias
This range covers less common forms and unspecified cases of acute myeloid leukemia.
Code Comparison: When to Use Each Code
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C92.00 | Acute myeloblastic leukemia not having achieved remission | Use when AML is diagnosed and has not achieved remission. |
|
| C92.01 | Acute myeloblastic leukemia, in remission | Use when AML is in documented remission. |
|
| C92.02 | Acute myeloblastic leukemia, in relapse | Use when AML has relapsed after a period of remission. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information: ICD-10 code for acute myeloblastic leukemia
Essential facts and insights about Acute Myeloblastic Leukemia
Primary ICD-10-CM Codes for acute myeloblastic leukemia
Decision Criteria
clinical Criteria
- Presence of ≥20% myeloblasts in bone marrow
documentation Criteria
- Documented genetic markers confirming AML
Applicable To
- AML with ≥20% myeloblasts
Excludes
- Acute promyelocytic leukemia (C92.4-)
Clinical Validation Requirements
- Bone marrow or peripheral blood showing ≥20% myeloblasts
- Genetic testing confirming AML subtype
Code-Specific Risks
- Ensure specificity to avoid using non-billable C92.0.
Coding Notes
- Ensure genetic markers and blast percentage are documented.
C92.01 - Acute myeloblastic leukemia, in remission
Use when AML is in documented remission.
Applicable To
- AML with <5% blasts
Excludes
- Relapsed AML (C92.02)
Clinical Validation Requirements
- Bone marrow showing <5% blasts
- Documented complete remission status
Coding Notes
Document remission criteria including blast percentage and blood counts.
C92.02 - Acute myeloblastic leukemia, in relapse
Use when AML has relapsed after a period of remission.
Applicable To
- AML with ≥20% blasts after remission
Excludes
- AML not in remission (C92.00)
Clinical Validation Requirements
- Bone marrow or peripheral blood showing ≥20% blasts post-remission
- Documented relapse status
Coding Notes
Document relapse with supporting lab results and previous remission dates.
Ancillary Codes
Additional codes that should be used in conjunction with the main diagnosis codes when applicable.
Thrombocytopenia
D59.1Differential Codes
Alternative codes to consider when ruling out similar conditions to the primary diagnosis.
Documentation & Coding Risks
Avoid these common documentation and coding issues when documenting Acute Myeloblastic Leukemia to ensure proper reimbursement, maintain compliance, and reduce audit risk. These guidelines are particularly important when using ICD-10 code C92.00.
Impact
Clinical: Impacts treatment decisions and monitoring., Regulatory: Non-compliance with documentation standards., Financial: Potential for incorrect billing and reimbursement.
Mitigation Strategy
Ensure remission status is updated in each patient visit note., Use templates to guide documentation.
Impact
Reimbursement: Incorrect DRG assignment leading to financial loss., Compliance: Non-compliance with coding specificity requirements., Data Quality: Inaccurate data for clinical and research purposes.
Mitigation Strategy
Ensure use of specific codes C92.00, C92.01, or C92.02.
Impact
Incorrect coding of remission status can lead to audit findings.
Mitigation Strategy
Implement regular training on remission status documentation.
Documentation errors, coding pitfalls, and audit risks are interconnected aspects of medical coding and billing. Addressing all three areas helps ensure accurate coding, optimal reimbursement, and regulatory compliance.
Frequently Asked Questions
Common questions about ICD-10 coding for Acute Myeloblastic Leukemia, with expert answers to help guide accurate code selection and documentation.
Documentation Templates for Acute Myeloblastic Leukemia
Use these documentation templates to ensure complete and accurate documentation for Acute Myeloblastic Leukemia. These templates include all required elements for proper coding and billing.
AML Diagnosis and Treatment Plan
Specialty: OncologyRequired Elements
- Patient history
- Lab results
- Genetic markers
- Treatment plan
Example Documentation
Examples: Poor vs. Good Documentation
Poor Documentation Example
Good Documentation Example
Explanation
Need help with ICD-10 coding for Acute Myeloblastic Leukemia? Ask your questions below.